Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Human Urine Metabolome Study Envisions New Diagnostic Era

...

6 Sep 2013

More than 3,000 chemicals or "metabolites" can be detected in urine, say researchers

Researchers at the University of Alberta announced today that they have determined the chemical composition of human urine. The study, which took more than seven years and involved a team of nearly 20 researchers, has revealed that more than 3,000 chemicals or "metabolites" can be detected in urine.

6 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

BTNL2 gene mutation that impacts immune function increases risk of prostate cancer

A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production - both of which impact immune function - increase the risk of developing prostate cancer.

30 Aug 2013

TAP block procedure poses no significant risks to patients and cuts postoperative use of narcotics

Surgeons at University Hospitals Case Medical Center, Cleveland, are working to reduce serious complications that have been known to occur with colorectal operations.

29 Aug 2013

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals Inc. announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.

26 Aug 2013

Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

A statistical model accounting for dozens of different genes in combination-and the interactions between them-is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease (CD), reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

26 Aug 2013

Understanding genetic factors that affect Crohn's disease risk

A statistical model accounting for dozens of different genes in combination—and the interactions between them—is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America.

23 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

Probiotic does not prevent clinical relapse in patients with Crohn's disease

Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

16 Aug 2013

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has approved the company's Investigational New Drug application to begin the Phase 2 clinical study of RBX2660 for the treatment of recurrent Clostridium difficile infection.

30 Jul 2013

Researchers discover mechanism that prevents immune system from spinning out of control

A team led by a University of Arizona researcher has discovered a previously unknown mechanism that prevents the immune system from going into overdrive, shedding light not only on how our body controls its response to pathogens but on conditions such as autoimmune diseases, allergies and chronic inflammation as well.

24 Jul 2013

GW Pharmaceuticals to expand marketing authorization for Sativex to France

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has submitted an application under the European Mutual Recognition Procedure seeking to expand the marketing authorization for Sativex into France for the treatment of spasticity due to Multiple Sclerosis.

22 Jul 2013

Researchers report that aerobic exercise can lessen or worsen ulcerative colitis symptoms

Aerobic exercise can lessen - or worsen - the symptoms of inflammatory bowel diseases such as ulcerative colitis, depending on the circumstances under which the exercise is undertaken, researchers report.

3 Jul 2013

Study reveals circadian disruption is a risk factor in alcoholic liver disease

Thirty percent of severe alcoholics develop liver disease, but scientists have not been able to explain why only a subset is at risk. A research team from Northwestern University and Rush University Medical Center now has a possible explanation: disrupted sleep and circadian rhythms can push those vulnerable over the edge to disease.

2 Jul 2013

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

1 Jul 2013

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Janssen Biotech, Inc. and Johnson & Johnson Innovation announced today the establishment of a research alliance with The Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease and the discovery of next generation therapeutic solutions.

27 Jun 2013

Reason for large increase in hospitalizations of children with IBD unclear, researchers report

The largest investigation to date has found a dramatic increase in the number of hospitalizations for children with inflammatory bowel disease during the past decade in the United States.

26 Jun 2013

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Santarus, Inc. and Pharming Group NV today announced that the U.S. Food and Drug Administration has accepted for filing the Biologics License Application for the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg.

18 Jun 2013

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Human Urine Metabolome Study Envisions New Diagnostic Era

More than 3,000 chemicals or "metabolites" can be detected in urine, say researchers

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

BTNL2 gene mutation that impacts immune function increases risk of prostate cancer

TAP block procedure poses no significant risks to patients and cuts postoperative use of narcotics

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

Understanding genetic factors that affect Crohn's disease risk

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Probiotic does not prevent clinical relapse in patients with Crohn's disease

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Researchers discover mechanism that prevents immune system from spinning out of control

GW Pharmaceuticals to expand marketing authorization for Sativex to France

Researchers report that aerobic exercise can lessen or worsen ulcerative colitis symptoms

Study reveals circadian disruption is a risk factor in alcoholic liver disease

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Reason for large increase in hospitalizations of children with IBD unclear, researchers report

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in